Published in J Cereb Blood Flow Metab on June 28, 2006
Changes in network activity with the progression of Parkinson's disease. Brain (2007) 2.46
Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci (2009) 2.16
Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proc Natl Acad Sci U S A (2007) 1.98
Metabolic brain networks associated with cognitive function in Parkinson's disease. Neuroimage (2006) 1.92
Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease. J Neurosci (2008) 1.56
Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol (2010) 1.56
Thalamic metabolism and symptom onset in preclinical Huntington's disease. Brain (2007) 1.54
Abnormal metabolic brain networks in Tourette syndrome. Neurology (2011) 1.54
Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease. J Neurosci (2010) 1.50
Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology (2008) 1.45
Scaled subprofile modeling of resting state imaging data in Parkinson's disease: methodological issues. Neuroimage (2010) 1.43
Assessment of the progression of Parkinson's disease: a metabolic network approach. Lancet Neurol (2007) 1.42
Parkinson's disease tremor-related metabolic network: characterization, progression, and treatment effects. Neuroimage (2010) 1.36
Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson's disease. Brain (2011) 1.34
Metabolic brain networks in translational neurology: concepts and applications. Ann Neurol (2012) 1.32
Quantification of Parkinson's disease-related network expression with ECD SPECT. Eur J Nucl Med Mol Imaging (2006) 1.24
Functional brain networks and abnormal connectivity in the movement disorders. Neuroimage (2011) 1.15
Parkinson's disease spatial covariance pattern: noninvasive quantification with perfusion MRI. J Cereb Blood Flow Metab (2010) 1.14
Abnormal regional brain function in Parkinson's disease: truth or fiction? Neuroimage (2008) 1.12
Network correlates of the cognitive response to levodopa in Parkinson disease. Neurology (2011) 1.04
Functional imaging of cerebral blood flow and glucose metabolism in Parkinson's disease and Huntington's disease. Mol Imaging Biol (2007) 1.03
The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow. Brain (2012) 1.01
Abnormal metabolic brain networks in a nonhuman primate model of parkinsonism. J Cereb Blood Flow Metab (2011) 0.99
Identification of disease-related spatial covariance patterns using neuroimaging data. J Vis Exp (2013) 0.98
Network correlates of disease severity in multiple system atrophy. Neurology (2012) 0.96
Metabolic network as a progression biomarker of premanifest Huntington's disease. J Clin Invest (2013) 0.95
Mechanisms of deep brain stimulation. J Neurophysiol (2015) 0.93
Parkinson's disease: increased motor network activity in the absence of movement. J Neurosci (2013) 0.93
Modulation of metabolic brain function by bilateral subthalamic nucleus stimulation in the treatment of Parkinson's disease. J Neurol (2009) 0.93
Sensorimotor connectivity in Parkinson's disease: the role of functional neuroimaging. Front Neurol (2014) 0.92
Characterization of disease-related covariance topographies with SSMPCA toolbox: effects of spatial normalization and PET scanners. Hum Brain Mapp (2013) 0.92
Functional brain networks in movement disorders: recent advances. Curr Opin Neurol (2012) 0.92
Abnormal metabolic network activity in REM sleep behavior disorder. Neurology (2014) 0.91
Parkinson's disease cognitive network correlates with caudate dopamine. Neuroimage (2013) 0.91
The utility of neuroimaging in the differential diagnosis of parkinsonian syndromes. Semin Neurol (2014) 0.90
Network modulation following sham surgery in Parkinson's disease. J Clin Invest (2014) 0.89
Functional reorganization of motor and limbic circuits after exercise training in a rat model of bilateral parkinsonism. PLoS One (2013) 0.88
Route and survey processing of topographical memory during navigation. Psychol Res (2010) 0.87
Multiclass classification of FDG PET scans for the distinction between Parkinson's disease and atypical parkinsonian syndromes. Neuroimage Clin (2013) 0.87
FDG PET in the Evaluation of Parkinson's Disease. PET Clin (2010) 0.87
Neuroimaging of Parkinson's disease: Expanding views. Neurosci Biobehav Rev (2015) 0.87
Biomarkers of Parkinson's disease: current status and future perspectives. Drug Discov Today (2012) 0.86
Consistent abnormalities in metabolic network activity in idiopathic rapid eye movement sleep behaviour disorder. Brain (2014) 0.85
Grey matter hypometabolism and atrophy in Parkinson's disease with cognitive impairment: a two-step process. Brain (2014) 0.84
Parkinson's disease-related spatial covariance pattern identified with resting-state functional MRI. J Cereb Blood Flow Metab (2015) 0.84
Modulation of Abnormal Metabolic Brain Networks by Experimental Therapies in a Nonhuman Primate Model of Parkinson Disease: An Application to Human Retinal Pigment Epithelial Cell Implantation. J Nucl Med (2016) 0.83
Neural circuit modulation during deep brain stimulation at the subthalamic nucleus for Parkinson's disease: what have we learned from neuroimaging studies? Brain Connect (2013) 0.82
Abnormal metabolic pattern associated with cognitive impairment in Parkinson's disease: a validation study. J Cereb Blood Flow Metab (2015) 0.81
The assessment of neurological systems with functional imaging. Brain Lang (2006) 0.81
Abnormal network topographies and changes in global activity: absence of a causal relationship. Neuroimage (2012) 0.80
Brain energization in response to deep brain stimulation of subthalamic nuclei in Parkinson's disease. J Cereb Blood Flow Metab (2011) 0.79
Parkinson's disease-related perfusion and glucose metabolic brain patterns identified with PCASL-MRI and FDG-PET imaging. Neuroimage Clin (2014) 0.79
Metabolic networks for assessment of therapy and diagnosis in Parkinson's disease. Mov Disord (2009) 0.79
Cerebral activations related to ballistic, stepwise interrupted and gradually modulated movements in Parkinson patients. PLoS One (2012) 0.79
Brain glucose metabolism in adults with ataxia-telangiectasia and their asymptomatic relatives. Brain (2014) 0.79
Independent component analysis of resting state activity in pediatric obsessive-compulsive disorder. Hum Brain Mapp (2014) 0.78
Quantifying significance of topographical similarities of disease-related brain metabolic patterns. PLoS One (2014) 0.78
The neurobiology and neural circuitry of cognitive changes in Parkinson's disease revealed by functional neuroimaging. Mov Disord (2012) 0.78
Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET. Mov Disord (2015) 0.77
Functional neuroimaging in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 0.77
Brain metabolism and autoantibody titres predict functional impairment in systemic lupus erythematosus. Lupus Sci Med (2015) 0.76
Dysfunctional putamen modulation during bimanual finger-to-thumb movement in patients with Parkinson's disease. Front Hum Neurosci (2015) 0.76
Classification of Parkinsonian syndromes from FDG-PET brain data using decision trees with SSM/PCA features. Comput Math Methods Med (2015) 0.76
Assessing cerebral glucose metabolism in patients with idiopathic rapid eye movement sleep behavior disorder. J Cereb Blood Flow Metab (2015) 0.76
Parkinson's disease-related network topographies characterized with resting state functional MRI. Hum Brain Mapp (2016) 0.75
A brain network response to sham surgery. J Clin Invest (2014) 0.75
Disrupted brain metabolic connectivity in a 6-OHDA-induced mouse model of Parkinson's disease examined using persistent homology-based analysis. Sci Rep (2016) 0.75
Regional covariance patterns of gray matter alterations in Alzheimer's disease and its replicability evaluation. J Magn Reson Imaging (2013) 0.75
Reverse Translation in Parkinson Disease. J Nucl Med (2016) 0.75
Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson's disease. JCI Insight (2017) 0.75
Effects of levodopa on regional cerebral metabolism and blood flow. Mov Disord (2014) 0.75
Abnormalities of regional brain function in Parkinson's disease: a meta-analysis of resting state functional magnetic resonance imaging studies. Sci Rep (2017) 0.75
Brain network markers of abnormal cerebral glucose metabolism and blood flow in Parkinson's disease. Neurosci Bull (2014) 0.75
Metabolic network expression in parkinsonism: Clinical and dopaminergic correlations. J Cereb Blood Flow Metab (2016) 0.75
The effect of 18F-FDG-PET image reconstruction algorithms on the expression of characteristic metabolic brain network in Parkinson's disease. Phys Med (2017) 0.75
Abnormal metabolic brain network associated with Parkinson's disease: replication on a new European sample. Neuroradiology (2017) 0.75
Intraclass correlations: uses in assessing rater reliability. Psychol Bull (1979) 71.07
Measurement error. BMJ (1996) 6.18
The role of radiotracer imaging in Parkinson disease. Neurology (2005) 3.02
Network modulation in the treatment of Parkinson's disease. Brain (2006) 2.52
Precision of the CASL-perfusion MRI technique for the measurement of cerebral blood flow in whole brain and vascular territories. J Magn Reson Imaging (2003) 1.99
The metabolic topography of parkinsonism. J Cereb Blood Flow Metab (1994) 1.89
Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease. Neuroimage (2006) 1.84
Functional correlates of pallidal stimulation for Parkinson's disease. Ann Neurol (2001) 1.65
Metabolic correlates of pallidal neuronal activity in Parkinson's disease. Brain (1997) 1.59
Metabolic correlates of levodopa response in Parkinson's disease. Neurology (2001) 1.50
Reproducibility of regional metabolic covariance patterns: comparison of four populations. J Nucl Med (1999) 1.48
A regional covariance approach to the analysis of functional patterns in positron emission tomographic data. J Cereb Blood Flow Metab (1991) 1.36
Primary dystonia: is abnormal functional brain architecture linked to genotype? Ann Neurol (2002) 1.35
Executive processes in Parkinson's disease: FDG-PET and network analysis. Hum Brain Mapp (2004) 1.26
Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med (1998) 1.22
Neuroimaging and therapeutics in movement disorders. NeuroRx (2005) 1.17
The metabolic pathology of dopa-responsive dystonia. Ann Neurol (2005) 1.14
Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: a PET study of resting-state glucose metabolism. Brain (2001) 1.13
Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients. J Nucl Med (1997) 1.12
Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism. Mov Disord (2002) 1.12
Reproducibility of cerebral glucose metabolic measurements in resting human subjects. J Cereb Blood Flow Metab (1988) 1.09
Intersubject variability and reproducibility of 15O PET studies. J Cereb Blood Flow Metab (2006) 1.05
Functional brain imaging in Parkinson's disease. Adv Neurol (2003) 1.03
Reproducibility of 99mTc-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson's disease. J Nucl Med (2004) 1.00
Reproducibility and discriminating ability of fluorine-18-6-fluoro-L-Dopa PET in Parkinson's disease. J Nucl Med (1996) 0.97
Reproducibility of resting cerebral blood flow measurements with H2(15)O positron emission tomography in humans. J Cereb Blood Flow Metab (1993) 0.97
Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study. J Cereb Blood Flow Metab (2000) 0.93
Reproducibility of dopamine transporter density measured with 123I-FPCIT SPECT in normal control and Parkinson's disease patients. Ann Nucl Med (2004) 0.88
Reproducibility of cerebral glucose utilization measured by PET and the [18F]-2-fluoro-2-deoxy-d-glucose method in resting, healthy human subjects. Eur J Nucl Med (1990) 0.86
Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet (2007) 7.01
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol (2006) 5.49
Network modulation in the treatment of Parkinson's disease. Brain (2006) 2.52
Changes in network activity with the progression of Parkinson's disease. Brain (2007) 2.46
Cerebellothalamocortical connectivity regulates penetrance in dystonia. J Neurosci (2009) 2.01
Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proc Natl Acad Sci U S A (2007) 1.98
Metabolic brain networks associated with cognitive function in Parkinson's disease. Neuroimage (2006) 1.92
Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease. Neuroimage (2006) 1.84
A new approach to spatial covariance modeling of functional brain imaging data: ordinal trend analysis. Neural Comput (2005) 1.78
Differential cortical and subcortical activations in learning rotations and gains for reaching: a PET study. J Neurophysiol (2003) 1.71
Impaired sequence learning in carriers of the DYT1 dystonia mutation. Ann Neurol (2003) 1.63
Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease. J Neurosci (2008) 1.56
Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol (2010) 1.56
The differential effect of PD and normal aging on early explicit sequence learning. Neurology (2003) 1.52
Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease. J Neurosci (2010) 1.50
Learning and consolidation of visuo-motor adaptation in Parkinson's disease. Parkinsonism Relat Disord (2008) 1.44
Scaled subprofile modeling of resting state imaging data in Parkinson's disease: methodological issues. Neuroimage (2010) 1.43
Using imaging to identify psychogenic parkinsonism before deep brain stimulation surgery. Report of 2 cases. J Neurosurg (2011) 1.43
Assessment of the progression of Parkinson's disease: a metabolic network approach. Lancet Neurol (2007) 1.42
FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage (2005) 1.40
Abnormal metabolic networks in atypical parkinsonism. Mov Disord (2008) 1.39
Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann Neurol (2002) 1.39
Microstructural white matter changes in primary torsion dystonia. Mov Disord (2008) 1.38
Parkinson's disease tremor-related metabolic network: characterization, progression, and treatment effects. Neuroimage (2010) 1.36
Preclinical Huntington's disease: compensatory brain responses during learning. Ann Neurol (2006) 1.36
Differential diagnosis of parkinsonian syndromes using PCA-based functional imaging features. Neuroimage (2009) 1.36
Primary dystonia: is abnormal functional brain architecture linked to genotype? Ann Neurol (2002) 1.35
Hereditary dystonia as a neurodevelopmental circuit disorder: Evidence from neuroimaging. Neurobiol Dis (2010) 1.34
Cerebellothalamocortical pathway abnormalities in torsinA DYT1 knock-in mice. Proc Natl Acad Sci U S A (2011) 1.33
Increased cerebellar activation during sequence learning in DYT1 carriers: an equiperformance study. Brain (2007) 1.33
Metabolic brain networks in translational neurology: concepts and applications. Ann Neurol (2012) 1.32
Quantitative Brain PET. Comparison of 2D and 3D Acquisitions on the GE Advance Scanner. Clin Positron Imaging (1998) 1.31
Comparative analysis of striatal FDOPA uptake in Parkinson's disease: ratio method versus graphical approach. J Nucl Med (2002) 1.31
Gaucher disease ascertained through a Parkinson's center: imaging and clinical characterization. Mov Disord (2010) 1.31
Imaging essential tremor. Mov Disord (2010) 1.27
Executive processes in Parkinson's disease: FDG-PET and network analysis. Hum Brain Mapp (2004) 1.26
Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J Cereb Blood Flow Metab (2006) 1.26
Microstructural white matter changes in carriers of the DYT1 gene mutation. Ann Neurol (2004) 1.24
Metabolic correlates of subthalamic nucleus activity in Parkinson's disease. Brain (2008) 1.24
Quantification of Parkinson's disease-related network expression with ECD SPECT. Eur J Nucl Med Mol Imaging (2006) 1.24
Learning networks in health and Parkinson's disease: reproducibility and treatment effects. Hum Brain Mapp (2003) 1.23
Effects of serotonin transporter promoter polymorphisms on serotonin function. Neuropsychopharmacology (2004) 1.21
Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in Parkinsonism. Neuroimage (2004) 1.21
Dopamine cell implantation in Parkinson's disease: long-term clinical and (18)F-FDOPA PET outcomes. J Nucl Med (2009) 1.20
Neuroimaging and therapeutics in movement disorders. NeuroRx (2005) 1.17
Increased sensorimotor network activity in DYT1 dystonia: a functional imaging study. Brain (2010) 1.16
The metabolic topography of posthypoxic myoclonus. Neurology (2004) 1.16
The functional neuroanatomy of geriatric depression. Int J Geriatr Psychiatry (2009) 1.16
An examination of executive dysfunction associated with frontostriatal circuitry in Parkinson's disease. J Clin Exp Neuropsychol (2006) 1.15
Functional brain networks and abnormal connectivity in the movement disorders. Neuroimage (2011) 1.15
Dopaminergic suppression of brain deactivation responses during sequence learning. J Neurosci (2008) 1.15
The metabolic pathology of dopa-responsive dystonia. Ann Neurol (2005) 1.14
Parkinson's disease spatial covariance pattern: noninvasive quantification with perfusion MRI. J Cereb Blood Flow Metab (2010) 1.14
Abnormal regional brain function in Parkinson's disease: truth or fiction? Neuroimage (2008) 1.12
Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism. Mov Disord (2002) 1.12
L-Dopa infusion does not improve explicit sequence learning in Parkinson's disease. Parkinsonism Relat Disord (2006) 1.08
Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson's disease. Am J Psychiatry (2002) 1.06
Relationship between self-reported apathy and executive dysfunction in nondemented patients with Parkinson disease. Cogn Behav Neurol (2007) 1.06
Functional imaging of cerebral blood flow and glucose metabolism in Parkinson's disease and Huntington's disease. Mol Imaging Biol (2007) 1.03
Functional brain imaging in Parkinson's disease. Adv Neurol (2003) 1.03
Network biomarkers for the diagnosis and treatment of movement disorders. Neurobiol Dis (2008) 1.02
Cerebral glucose metabolism and D2/D3 receptor availability in young adults with cannabis dependence measured with positron emission tomography. Psychopharmacology (Berl) (2008) 1.02
Differential nitros(yl)ation of blood and tissue constituents during glyceryl trinitrate biotransformation in vivo. Proc Natl Acad Sci U S A (2004) 1.02